Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Sandra van Bijnen"'
Autor:
Merel A A, Opdam, Sophie, Benoy, Lise M, Verhoef, Sandra, Van Bijnen, Femke, Lamers-Karnebeek, René A M, Traksel, Petra, Vos, Alfons A, den Broeder, Jasper, Broen
Publikováno v:
Clinical Pharmacology and Therapeutics, 111, 1061-1065
Clinical Pharmacology and Therapeutics, 111, 5, pp. 1061-1065
Clinical Pharmacology and Therapeutics, 111, 5, pp. 1061-1065
Contains fulltext : 251806.pdf (Publisher’s version ) (Closed access) Patients with inflammatory rheumatic diseases (IRDs) do not have an increased risk for coronavirus disease 2019 (COVID-19) compared with the general population. However, it remai
Publikováno v:
Leukemia Research, 105
Purpose To determine the safety of tipifarnib in combination with escalating doses of bortezomib and to determine the maximum tolerated dose in patients with untreated high-risk MDS and oligoblastic acute myeloid leukemia, who were not eligible for i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5bc353cda6e7628e6876e50caecdeea3
https://doi.org/10.1016/j.leukres.2021.106573
https://doi.org/10.1016/j.leukres.2021.106573
Autor:
Sandra van Bijnen, Maaike Boonstra, Cornelia van den Enden, Julia Spierings, Anne Schouffoer, Jacob M. van Laar, Thomas Huizinga, Alexandre Voskuyl, Walter van der Velden, Frank van den Hoogen, Jeska de Vries, Madelon Vonk
Publikováno v:
Saturday, 15 June 2019.
Autor:
Jianguo Tao, Sheng Wei, Nicole Fortenbery, Dahui Qin, Pearlie K. Epling-Burnette, Erika A. Eksioglu, Theo de Witte, Xianghong Chen, Junmin Zhou, Huaquan Wang, Pingyan Cheng, Harry Dolstra, Alan F. List, Dmitry I. Gabrilovich, Sandra van Bijnen, Julie Y. Djeu, Sarah S. Donatelli, Je-In Youn, John P. Cannon, Ling Zhang
Publikováno v:
Journal of Clinical Investigation, 123, 4595-611
Journal of Clinical Investigation, 123, 11, pp. 4595-611
Journal of Clinical Investigation, 123, 11, pp. 4595-611
Contains fulltext : 140530.pdf (Publisher’s version ) (Open Access) Myelodysplastic syndromes (MDS) are age-dependent stem cell malignancies that share biological features of activated adaptive immune response and ineffective hematopoiesis. Here we
Autor:
Petra Muus, Sandra van Bijnen, Henry A. van Swieten, J.M.J. Mourisse, Harry Vermeer, Theo de Witte
Publikováno v:
European Journal of Haematology. 87:376-378
Publikováno v:
Journal of Hematopathology, 6, 2, pp. 71-82
Journal of Hematopathology, 6, 71-82
Journal of Hematopathology, 6, 71-82
Paroxysmal nocturnal hemoglobinuria (PNH) is a disease with variable presentation, including classical PNH (cPNH) and PNH with aplastic anemia (AA-PNH). Here, we describe bone marrow (BM) histology related to clinical findings in 67 patients with a P
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::503372058555928f6820c966a0c930d2
https://hdl.handle.net/2066/118075
https://hdl.handle.net/2066/118075
Autor:
Peter A. W. te Boekhorst, Senada Koljenović, Roos S van Rijn, Theo de Witte, Sandra van Bijnen, Petra Muus
Publikováno v:
British Journal of Haematology, 157, 6, pp. 762-3
British Journal of Haematology, 157, 762-3
British Journal of Haematology, 157(6), 762-763. Wiley-Blackwell Publishing Ltd
British Journal of Haematology, 157, 762-3
British Journal of Haematology, 157(6), 762-763. Wiley-Blackwell Publishing Ltd
Item does not contain fulltext 01 juni 2012
Publikováno v:
Blood. 122:1235-1235
Background Paroxysmal Nocturnal Hemoglobinuria (PNH) is a heterogeneous disease characterized by complement-mediated hemolysis and an extremely high risk of thrombosis. Eculizumab, a monoclonal antibody to complement factor C5, effectively blocks hem
Publikováno v:
Blood. 118:5054-5054
Abstract 5054 Cytoxic T-lymphocyte-associated antigen-4 (CTLA-4) is a co-inhibitory molecule normally expressed on activated effector T cells and a subset of regulatory T cells. However, it has been reported also to be expressed on acute myeloid leuk
Autor:
Timothy R D J Radstake, Marta Cossu, Sandra van Bijnen, Harry Dolstra, Frank Preijers, Jan Spanholtz
Publikováno v:
Journal of Translational Medicine
Rheumatoid arthritis (RA) and psoriatic arthritis (PsA) are immune-mediated diseases which partly share clinical features, but differentiate in the mechanisms which lead to aberrant immune responses. Natural killer (NK) cells tune the innate immune r